Codexis Inc

Research Codexis Inc (CDXS) on Bullrun: market cap USD 153.53M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 153.53M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 70.39M-USD 43.97M-USD 23.85M86.7%-0.5USD 50.79MUSD 40.11MUSD 50.53M
FY2024USD 59.35M-USD 65.28M-USD 53.72M72.6%-0.89USD 19.26MUSD 28.91MUSD 66.93M
FY2023USD 70.14M-USD 76.24M-USD 57.06M81.7%-1.12USD 65.12MUSD 0USD 86.62M
FY2022USD 138.59M-USD 33.59MUSD 2.98M72.6%-0.51USD 113.98MUSD 46.11MUSD 144.80M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 153.53Mn/an/an/a
20252025-12-31USD 147.48Mn/an/an/a
20242024-12-31USD 390.42Mn/an/an/a
20232023-12-29USD 212.98Mn/an/an/a
20222022-12-30USD 306.10Mn/an/an/a
20212021-12-31USD 2.04Bn/an/an/a

About Codexis Inc

Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Codexis Inc's market cap?

Codexis Inc's market capitalization is USD 153.53M.

What does Codexis Inc do?

Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc.